Michael Robert A.

SEC source: 0001699914-26-000004 · form4-03032026_110308.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,737

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,251

Underlying: Common Stock · 81,251 shares

Expires 2036-02-17

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,260

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,136

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,684

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001699914-26-000002 · form4-02202026_060201.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,654

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

SEC source: 0001415889-25-006583 · form4-03042025_050314.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,821

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,333

Underlying: Common Stock · 83,333 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,007

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,553

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,523

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,377

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · derivative · entry 7

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,140 shares

Expires 2026-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · derivative · entry 6

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,420 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · nonDerivative · entry 5

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,645

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $176.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,964

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.39 to $176.57, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-006163 · form4-03012024_050320.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,964

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,888

Underlying: Common Stock · 59,888 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,602

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,572

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,426

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004416 · form4-02202024_050205.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · PRES & CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,210

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-23-003821 · form4-03022023_040309.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,645

SEC source: 0001415889-23-002935 · form4-02212023_100213.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,577

Underlying: Common Stock · 45,577 shares

Expires 2033-02-15

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,193 on February 16, 2024, 15,192 on February 16, 2025, and 15,192 on February 16, 2026.

SEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,980

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,832

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,614

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001415889-23-002935 · form4-02212023_100213.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,394

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

SEC source: 0001179110-22-001828 · edgar.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,877

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.87 to $149.44 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-001828 · edgar.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,113

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.87 to $148.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-001828 · edgar.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,050

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.875 to $147.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-22-001828 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,982

SEC source: 0001179110-22-001515 · edgar.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,161

Underlying: Common Stock · 48,161 shares

Expires 2032-02-16

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,054 on February 17, 2023, 16,054 on February 17, 2024, and 16,053 on February 17, 2025.

SEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,268

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were release d on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.

SEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,703

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.

SEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,483

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.

SEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,626

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.

SEC source: 0001179110-21-002608 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,877

SEC source: 0001179110-21-002052 · edgar.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,217

Underlying: Common Stock · 65,217 shares

Expires 2031-02-17

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022, 21,739 on February 18, 2023, and 21,739 on February 18, 2024.

SEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,883

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.

SEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,663

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.

SEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,804

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.

SEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,319

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.

SEC source: 0001179110-20-002857 · edgar.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,270

SEC source: 0001179110-20-002133 · edgar.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,382

Underlying: Common Stock · 106,382 shares

Expires 2030-02-19

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,461 on February 20, 2021, 35,461 on February 20, 2022, and 35,460 on February 20, 2023.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,708

F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,849

F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.

SEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,364

F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.